相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
Glenn E. Palomaki et al.
GENETICS IN MEDICINE (2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism
Linnea M. Baudhuin et al.
CLINICAL BIOCHEMISTRY (2007)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
Adjuvant treatment of colorectal cancer
Brian M. Wolpin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity
Roshni P. Ramchandani et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American intergroup trial
Richard M. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Management of advanced colorectal cancer: state of the art
M. Saunders et al.
BRITISH JOURNAL OF CANCER (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Optimal treatment of metastatic colorectal cancer
Anna Pessino et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan
Swati Nagar et al.
DRUG METABOLISM REVIEWS (2006)
Systemic therapy for metastatic colorectal cancer: Current options, current evidence
H Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Rapid detection of UGT1A1 gene polymorphisms by newly developed invader assay
Y Hasegawa et al.
CLINICAL CHEMISTRY (2004)
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
A Font et al.
INVESTIGATIONAL NEW DRUGS (2003)
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance
JO Miners et al.
TOXICOLOGY (2002)
The treatment of advanced colorectal cancer: where are we now and where do we go?
E Van Cutsem et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2002)